Finance

Lists
TNYA:NASDAQ
Tenaya Therapeutics Inc
$0.35
+0.49%
(+0.0017) 1D
$0.36
+3.81% (+0.013)
After hours
Closed: Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TNYA...
Open
$0.35
High
$0.36
Low
$0.33
Mkt. cap
79.02M
Avg. vol.
3.46M
Volume
1.31M
52-wk high
$1.46
52-wk low
$0.30
EPS
-$0.49
Beta
2.88
Shares outstanding
227.93M
No. of employees
70
Open
$0.35
High
$0.36
Low
$0.33
Mkt. cap
79.02M
Avg. vol.
3.46M
Volume
1.31M
52-wk high
$1.46
52-wk low
$0.30
EPS
-$0.49
Beta
2.88
Shares outstanding
227.93M
No. of employees
70
News stories
From web sources and news partners
About Tenaya Therapeutics Inc
CEO-
Employees70
Founded2016
HeadquartersSouth San Francisco, California, United States
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 3 analysts giving stock ratings to TNYA in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for TNYA in the last 3 months.
Highest
Current $0.35
$6.00 (+1,618.21%)
Average
$4.67 (+1,237.34%)
Lowest
$3.00 (+759.11%)
Analyst
Recommendation
Action
Price target
Projected
Date
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$5.00
+1,331.8%
11/04/2026
Yasmeen Rahimi
Piper Sandler
Buy
Reiterated
$6.00
+1,618.2%
11/05/2026
Joseph Pantginis
H.C. Wainwright
Buy
Maintained
$3.00
+759.1%
11/05/2026
Cory Jubinville, PhD
LifeSci Capital
Buy
Maintained
$4.00
+1,045.5%
08/06/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/06/2026
Andy Hsieh
William Blair
Buy
Maintained
-
-
07/29/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
$2.00
+472.7%
06/03/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$8.00
+2,191%
05/15/2026
Last report
Nov 4, 2026
Fiscal period
Q3 2026
-$0.08 / -$0.09
+15.26%beat
Revenue / Est. (USD)
1.70M / 800.00K
+112.13%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
225.00K
1.11M
1.70M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
14.80M
14.84M
16.60M
14.87M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.98M
5.45M
5.41M
5.65M
Operating expense
20.78M
20.29M
22.01M
20.51M
Total operating expenses
20.78M
20.29M
22.01M
20.51M
Operating income
-20.78M
-20.06M
-20.90M
-18.82M
Other non operating income
25.00K
-
-1.37M
-1.00K
EBT including unusual items
-20.18M
-19.27M
-43.39M
-18.94M
EBT excluding unusual items
-20.18M
-19.27M
-21.57M
-18.18M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-20.18M
-19.27M
-43.39M
-18.94M
Net profit margin
-
-8,565.33%
-3,909.28%
-1,115.97%
Earnings per share
-0.12
-0.09
-0.09
-0.08
Interest and investment income
575.00K
793.00K
697.00K
635.00K
Interest expense
-
-
-
-
Net interest expenses
575.00K
793.00K
697.00K
635.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-18.95M
-18.30M
-19.20M
-18.42M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps